...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
【24h】

Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.

机译:强啡肽A1-13通过阿片受体机制引起人类血清催乳素水平升高:性别差异以及对成瘾治疗中多巴胺能基调的影响。

获取原文
获取原文并翻译 | 示例

摘要

Dynorphin peptides act preferentially at kappa- as well as mu- and delta-opioid receptors. This study was conducted to determine whether dynorphin peptides act to lower dopaminergic tone in the tuberoinfundibular system, resulting in elevated serum prolactin levels and, if so, whether such an effect is mediated by the opioid receptors. Dose-related increases in serum prolactin levels were observed after dynorphin A1-13 was administered i.v. in doses of 120 and 500 micrograms/kg to healthy human volunteers with no history of drug or alcohol abuse. Studies were then conducted to determine whether this effect is opioid receptor mediated and, if so, whether at kappa- or mu types. Pretreatment with the opioid antagonist nalmefene (30 mg i.v.), which has high affinity at both mu- and kappa-opioid receptors, caused a greater attenuation in dynorphin A1-13-stimulated increases in serum prolactin levels than pretreatment with similarly high doses of naloxone, an antagonist with lower affinity for both mu- and kappa-opioid receptors. These results suggest dynorphin A1-13 lowers tuberoinfundibular dopaminergic tone through action at kappa- and possibly mu-opioid receptors. Female subjects were significantly more responsive to the prolactin effects of dynorphin than were male subjects. Dynorphin gene expression, dynorphin peptides, and kappa-opioid receptor gene expression and binding have been shown to be altered in response to cocaine administration. Also, both dynorphin peptides and synthetic kappa-opioid agonists have been shown to lower dopamine levels in the nucleus accumbens and to attenuate cocaine-induced surges in dopamine levels. Thus, a dynorphin-like compound capable of reaching critical mesolimbic-mesocortical and nigrostriatal dopaminergic systems may be effective in the management of cocaine addiction.
机译:强啡肽肽优先作用于κ和μ阿片和δ阿片受体。进行这项研究是为了确定强啡肽是否在降低肺漏斗系统中的多巴胺能基调中起作用,从而导致血清催乳素水平升高,如果是,则这种作用是否由阿片受体介导。静脉注射强啡肽A1-13后观察到血清催乳素水平与剂量相关。对没有药物或酒精滥用史的健康人类志愿者的剂量为120和500微克/千克。然后进行研究以确定该作用是否是阿片受体介导的,如果是,则是在κ型还是μ型的。阿片拮抗剂纳美芬(30 mg iv)的预处理对mu和kappa阿片受体均具有高亲和力,与强啡肽A1-13刺激的血清催乳素水平升高相比,纳洛酮的减弱更大,一种对mu和阿片受体均具有较低亲和力的拮抗剂。这些结果表明强啡肽A1-13通过对κ受体和可能对μ阿片受体的作用而降低了肺漏斗性多巴胺能的语气。女性受试者对强啡肽的催乳激素作用的反应比男性受试者明显更高。强啡肽基因表达,强啡肽,以及κ-阿片受体基因表达和结合已显示可卡因给药后发生改变。同样,强啡肽和合成的阿片类阿片激动剂均显示降低伏隔核中的多巴胺水平,并减弱可卡因诱导的多巴胺水平激增。因此,能够达到关键的中膜边缘-介导的和黑质纹状体多巴胺能系统的强啡肽样化合物可能在可卡因成瘾的治疗中有效。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号